Inflammatory Marker Testing Identifies CD74 Expression in Melanoma Tumor Cells, and Its Expression Associates with Favorable Survival for Stage III MelanomaSühendan Ekmekçioglu, Elizabeth A. Grimm, Jason Roszik et al.|Clinical Cancer Research|2016Cited by 51
Cobimetinib plus atezolizumab for <i>RAS</i> and <i>NF</i>1/2-mutated poorly differentiated thyroid carcinoma.Sarah Hamidi, Ramona Dadu, Naifa L. Busaidy et al.|Journal of Clinical Oncology|2024Cited by 4